# A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

> **NCT02491463** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 73 (actual)

## Conditions studied

- Respiratory Synctial Virus Infections

## Interventions

- **BIOLOGICAL:** GSK3389245A_LD GROUP
- **BIOLOGICAL:** GSK3389245A_HD GROUP
- **BIOLOGICAL:** Bexsero
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02491463
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-23
- **Primary completion:** 2016-04-08
- **Final completion:** 2017-01-26
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02491463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02491463, "A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02491463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*